The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase ...

Mesoblast posts strong Ryoncil sales and secures new funding, with cash reserves set for upcoming clinical milestones. Mesoblast enhanced its financial flexibility this quarter, drawing US$75 million ...

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the ...

Growing revenue and broker optimism are boosting confidence. The post 3 reasons why this ASX biotech stock could double in value appeared first on The Motley Fool Australia.

Mesoblast focuses on therapies to treat autoimmune disorders. The company's resubmission of Ryoncil was given a Complete Response Letter by the FDA. The company will have a trial of Ryoncil on adults ...

Cell and gene therapy makers have to contend with a laundry list of concerns on the road to approval, including a complicated manufacturing process and often, some regulatory pushback. Facing what was ...

Mesoblast's Phase 3 trial in Chronic Heart Failure failed to meet its primary endpoint. We believe Mesoblast's stated positive results in the failed CHF trial used statistical methods and post-hoc ...

Mesoblast Ltd (NASDAQ:MESO) is among the best Australian stocks to buy in 2026. On April 14, Mesoblast Ltd (NASDAQ:MESO) announced that it has secured exclusive global rights to a patented technology ...

Operational and regulatory initiatives in support of the Company’s activities for regulatory meetings with United States Food & Drug Administration (FDA) in the coming quarters. These activities ...

Several analysts have recently downgraded their positions on the pharmaceutical stock. Mesoblast focuses on therapies derived from the cells of the bone marrow from healthy donors. The company lost ...

NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the United States Food and ...